FUSN Fusion Pharmaceuticals Inc
809
$21.55
$0.03
(0.14%)
| Watchers | 809 |
| 52-Wk Low | $2.31 |
| 52-Wk High | $21.58 |
| Market Cap | $1.83B |
| Volume | 15,674.00 |
| 52-Wk High | $21.58 |
| 52-Wk Low | $2.31 |
Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia StakeInvestopedia Headlines • 7 days ago
Bloomberg / Contributor / Getty Images
Key TakeawaysBillionaire Stanley Druckenmiller added more than three dozen new positions to his portfolio in the first quarter, including Apple, Reddit...
Share to Feed
:max_bytes(150000):strip_icc()/GettyImages-1258506630-3cc588efbd0045219e360b66b93fb357.jpg)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, DRQ, CVLY, FUSN SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, DRQ, CVLY, FUSN PR Newswire NEW YORK, May 13, 2024 NEW...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, DRQ, FUSN SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, DRQ, FUSN PR Newswire NEW YORK, May 10, 2024 NEW YORK, May 10...
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer Fusion Pharmaceuticals...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Fusion Pharmaceuticals Inc. (NasdaqGS: FUSN) to...
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical...
Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm PR Newswire NEW YORK, April 26, 2024 NEW YORK...
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, JBT SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, JBT PR Newswire NEW YORK, April 9, 2024 NEW YORK, April...
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024 Fusion Pharmaceuticals Announces Presentation...